Harvard Bioscience slumps after weak revenue forecast

Shares of Harvard Bioscience HBIO.O down 12.1% at 67 cents premarket

Co expects Q1 revenue between $19 million and $21 million, below analysts' estimates of $22.95 million - data compiled by LSEG

The company is also exploring alternative capital sources for refinancing outstanding indebtedness by June 30

As of last close, HBIO down ~64% YTD